Pierrepont Therapeutics is focused on developing targeted treatments for primary mitochondrial and other rare genetic diseases. Its lead product candidate, PTI-501 (formerly ENTR-501), is a proprietary intracellular enzyme replacement therapy for the treatment of MNGIE, exclusively licensed from Entrada Therapeutics, Inc. (Nasdaq: TRDA). The company is based in Pittsburgh, PA. Founders including Daniel DiPietro have expertise and success in mitochondrial disease drug development and maintain relationships with KOLS, families, and patient advocacy groups in the mitochondrial disease community. The company intends to use newly raised funds to expand operations and its R&D sector. Pierrepont recently raised $500K in funding from The Mito Fund.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2024